Acute Lymphoblastic Leukemia

Previously Untreated

- Age ≥ 60
  - SWOG-A041703
    - Phase II Inotuzumab Ozogamicin Followed by Blinatumomab in Ph-Negative CD22-Positive B-Lineage ALL
    - PI: Coutre
    - ECOG-ACRIN

- Age 18-39
  - SWOGA041501
    - Phase III Inotuzumab Ozogamicin (Anti-CD22 Mab) vs Frontline Tx in NewlyDiagnosedPrecursor B-Cell ALL
    - PI: Liedtke
    - SWOG

Relapsed/Refractory

- Age ≥ 18
  - SWOG-A041703
    - Phase II Inotuzumab Ozogamicin Followed by Blinatumomab in Ph-Negative CD22-Positive B-Lineage ALL
    - PI: Coutre
    - ECOG-ACRIN

CD19-Positive

- CCT052
  - Phase I Open Label Dose Escalation Study of YTB323 in CLL/SLL and DLBCL
  - PI: Coutre
  - Novartis